Pyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302

BACKGROUND: Hypoxic niches in solid tumors harbor therapy-resistant cells. Hypoxia-activated prodrugs (HAPs) have been designed to overcome this resistance and, to date, have begun to show clinical efficacy. However, clinical HAPs activity could be improved. In this study, we sought to identify non-...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Cancer Metab
Main Authors: Wojtkowiak, Jonathan W, Cornnell, Heather C, Matsumoto, Shingo, Saito, Keita, Takakusagi, Yoichi, Dutta, Prasanta, Kim, Munju, Zhang, Xiaomeng, Leos, Rafael, Bailey, Kate M, Martinez, Gary, Lloyd, Mark C, Weber, Craig, Mitchell, James B, Lynch, Ronald M, Baker, Amanda F, Gatenby, Robert A, Rejniak, Katarzyna A, Hart, Charles, Krishna, Murali C, Gillies, Robert J
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2015
נושאים:
Research
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4310189/
https://ncbi.nlm.nih.gov/pubmed/25635223
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40170-014-0026-z
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים